JP2013523629A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013523629A5 JP2013523629A5 JP2013500647A JP2013500647A JP2013523629A5 JP 2013523629 A5 JP2013523629 A5 JP 2013523629A5 JP 2013500647 A JP2013500647 A JP 2013500647A JP 2013500647 A JP2013500647 A JP 2013500647A JP 2013523629 A5 JP2013523629 A5 JP 2013523629A5
- Authority
- JP
- Japan
- Prior art keywords
- cys
- thr
- lys
- phe
- trp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 235000014113 dietary fatty acids Nutrition 0.000 claims 13
- 239000000194 fatty acid Substances 0.000 claims 13
- 229930195729 fatty acid Natural products 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- -1 fatty acid salts Chemical class 0.000 claims 10
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 102000005157 Somatostatin Human genes 0.000 claims 3
- 108010056088 Somatostatin Proteins 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- 229960000553 somatostatin Drugs 0.000 claims 3
- 230000037317 transdermal delivery Effects 0.000 claims 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 claims 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 claims 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims 2
- 239000003961 penetration enhancing agent Substances 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 claims 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 claims 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 1
- HZUFJLNYZNGZLC-UHFFFAOYSA-N 6-amino-n-[1-[[1-[(1-amino-3-hydroxy-1-oxobutan-2-yl)amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]-2-[[2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]-3-(4-chlorophenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1h-indol-3-y Chemical compound C=1NC2=CC=CC=C2C=1CC(NC(=O)C(CC=1C=CC(O)=CC=1)NC(=O)C(CC=1C=CC(Cl)=CC=1)NC(=O)C(N)CC=1C=CC=CC=1)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(C(=O)NC(C(O)C)C(N)=O)CC1=CC=CC=C1 HZUFJLNYZNGZLC-UHFFFAOYSA-N 0.000 claims 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 claims 1
- PSMFFFUWSMZAPB-UHFFFAOYSA-N Eukalyptol Natural products C1CC2CCC1(C)COCC2(C)C PSMFFFUWSMZAPB-UHFFFAOYSA-N 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 1
- 239000005642 Oleic acid Substances 0.000 claims 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 claims 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20100174A IE20100174A1 (en) | 2010-03-25 | 2010-03-25 | Transdermal administration of peptides |
| IE2010/0174 | 2010-03-25 | ||
| PCT/IE2011/000019 WO2011117851A1 (en) | 2010-03-25 | 2011-03-23 | Transdermal administration of peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013523629A JP2013523629A (ja) | 2013-06-17 |
| JP2013523629A5 true JP2013523629A5 (OSRAM) | 2014-05-08 |
Family
ID=44210069
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013500647A Ceased JP2013523629A (ja) | 2010-03-25 | 2011-03-23 | ペプチドの経皮投与方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20130085105A1 (OSRAM) |
| EP (1) | EP2550005A1 (OSRAM) |
| JP (1) | JP2013523629A (OSRAM) |
| KR (1) | KR20130062275A (OSRAM) |
| CN (1) | CN102883735A (OSRAM) |
| AU (1) | AU2011231173A1 (OSRAM) |
| BR (1) | BR112012022377A2 (OSRAM) |
| CA (1) | CA2792470A1 (OSRAM) |
| IE (1) | IE20100174A1 (OSRAM) |
| MX (1) | MX2012010343A (OSRAM) |
| RU (1) | RU2012145278A (OSRAM) |
| WO (1) | WO2011117851A1 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5486690B2 (ja) | 2009-11-16 | 2014-05-07 | イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ | メラノコルチン受容体リガンドの医薬組成物 |
| MX343499B (es) * | 2010-03-15 | 2016-11-08 | Ipsen Pharma Sas | Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento. |
| EP3106159A1 (en) | 2010-05-12 | 2016-12-21 | Radius Health, Inc. | Therapeutic regimens |
| JP5965909B2 (ja) | 2010-09-28 | 2016-08-10 | ラジウス ヘルス,インコーポレイテッド | 選択的アンドロゲン受容体モジュレーター |
| US9295636B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US20140271938A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9393264B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US20140271937A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9314433B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9339457B2 (en) | 2013-03-13 | 2016-05-17 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US20140271731A1 (en) | 2013-03-13 | 2014-09-18 | Transdermal Biotechnology, Inc. | Cardiovascular disease treatment and prevention |
| US9387159B2 (en) | 2013-03-13 | 2016-07-12 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9314423B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Hair treatment systems and methods using peptides and other compositions |
| US9687520B2 (en) | 2013-03-13 | 2017-06-27 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9750787B2 (en) | 2013-03-13 | 2017-09-05 | Transdermal Biotechnology, Inc. | Memory or learning improvement using peptide and other compositions |
| US9320758B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Brain and neural treatments comprising peptides and other compositions |
| US9393265B2 (en) | 2013-03-13 | 2016-07-19 | Transdermal Biotechnology, Inc. | Wound healing using topical systems and methods |
| US9849160B2 (en) | 2013-03-13 | 2017-12-26 | Transdermal Biotechnology, Inc. | Methods and systems for treating or preventing cancer |
| US9314422B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9724419B2 (en) | 2013-03-13 | 2017-08-08 | Transdermal Biotechnology, Inc. | Peptide systems and methods for metabolic conditions |
| US9314417B2 (en) | 2013-03-13 | 2016-04-19 | Transdermal Biotechnology, Inc. | Treatment of skin, including aging skin, to improve appearance |
| US9241899B2 (en) | 2013-03-13 | 2016-01-26 | Transdermal Biotechnology, Inc. | Topical systems and methods for treating sexual dysfunction |
| US9295637B2 (en) * | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Compositions and methods for affecting mood states |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| EP2979702A4 (en) * | 2013-03-25 | 2016-11-16 | Zeria Pharm Co Ltd | GASTROKINETIC POSTPRANDIAL MEDIUM |
| CA2943611A1 (en) | 2014-03-28 | 2015-10-01 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| PL3166967T3 (pl) * | 2014-09-14 | 2023-07-24 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Syntetyczne ligandy receptora somatostatyny |
| CA2984357A1 (en) | 2015-04-29 | 2016-11-03 | Radius Pharmaceuticals, Inc. | Methods for treating cancer |
| US12427121B2 (en) | 2016-05-05 | 2025-09-30 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine compositions |
| US12433850B2 (en) | 2016-05-05 | 2025-10-07 | Aquestive Therapeutics, Inc. | Enhanced delivery epinephrine and prodrug compositions |
| KR20190005199A (ko) | 2016-05-05 | 2019-01-15 | 어퀘스티브 테라퓨틱스, 아이엔씨. | 강화된 전달 에프네프린 조성물 |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| CA3027563C (en) | 2016-06-22 | 2024-07-02 | Ellipses Pharma Ltd | AR+ METHODS FOR BREAST CANCER TREATMENT |
| JP7481115B2 (ja) | 2017-01-05 | 2024-05-10 | ラジウス ファーマシューティカルズ,インコーポレイテッド | Rad1901-2hclの多形性形態 |
| KR101786914B1 (ko) * | 2017-01-31 | 2017-11-15 | 주식회사 삼양사 | 피부 리프팅 또는 탄력 개선을 위한 점착성 탄력 밴드 |
| CN107226840A (zh) * | 2017-05-04 | 2017-10-03 | 西安交通大学 | 一种细胞穿膜肽透皮吸收促进剂及其制备方法和应用 |
| EP3687508A1 (en) * | 2017-09-26 | 2020-08-05 | Aquestive Therapeutics, Inc. | Delivery pharmaceutical compositions including permeation enhancers |
| US11969460B2 (en) * | 2018-06-08 | 2024-04-30 | Saint Louis University | Methods and compositions for treating decreased cognitive ability |
| IL279853B2 (en) | 2018-07-04 | 2025-01-01 | Radius Pharmaceuticals Inc | Polymorphic forms of RAD 1901-2HCL |
| IT201800009384A1 (it) * | 2018-10-11 | 2020-04-11 | Cosmo Srl | Peptide for cosmetic application |
| CN119390714A (zh) | 2019-02-12 | 2025-02-07 | 雷迪厄斯制药公司 | 方法和化合物 |
| DE102020130492A1 (de) * | 2020-11-18 | 2022-05-19 | Lts Lohmann Therapie-Systeme Ag. | Temperiersystem für eine Diffusionszelle, Diffusionszelle, Diffusionszellensystem, sowie Verfahren zur Temperierung in einer Diffusionszelle |
| WO2023281447A1 (en) * | 2021-07-07 | 2023-01-12 | Radius Health, Inc. | Methods of treating a cardiovascular ischemic event |
| US12465564B2 (en) | 2021-10-25 | 2025-11-11 | Aquestive Therapeutics, Inc. | Oral and nasal compositions and methods of treatment |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954975A (en) * | 1972-02-17 | 1976-05-04 | Ciba-Geigy Corporation | Salts of ACTH-peptides and processes for their manufacture |
| IL79134A (en) * | 1985-07-29 | 1991-06-10 | American Cyanamid Co | Continuous release peptide implants for parenteral administration |
| EP0671937A4 (en) * | 1992-10-16 | 1996-09-18 | Smithkline Beecham Corp | COMPOSITIONS FOR PHARMACEUTICAL EMULSIONS. |
| US6316414B1 (en) * | 2000-07-31 | 2001-11-13 | Dabur Research Foundation | Somatostatin analogs for the treatment of cancer |
| CA2450446A1 (en) * | 2001-06-25 | 2003-01-03 | Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R | Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof |
| US20030175329A1 (en) * | 2001-10-04 | 2003-09-18 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
| WO2006040447A1 (fr) * | 2004-10-07 | 2006-04-20 | L'oreal | Procédé de traitement cosmétique des fibres kératiniques et utilisation d'un inhibiteur de transglutaminase |
| US20060216242A1 (en) * | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
| AU2007233116B2 (en) * | 2006-03-30 | 2013-05-09 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
| WO2008008363A1 (en) * | 2006-07-11 | 2008-01-17 | Qps, Llc | Pharmaceutical compositions for sustained release delivery of peptides |
| GB0705264D0 (en) * | 2007-03-20 | 2007-04-25 | Pliva Istrazivanje I Razvoj D | Gel forming compounds |
| US20100196264A1 (en) * | 2007-05-18 | 2010-08-05 | The Brigham And Women's Hospital, Inc. | Use of somatostatin analogs in myocardial perfusion imaging |
| WO2009100222A1 (en) * | 2008-02-08 | 2009-08-13 | Qps Llc | Non-polymeric compositions for controlled drug delivery |
-
2010
- 2010-03-25 IE IE20100174A patent/IE20100174A1/en not_active IP Right Cessation
-
2011
- 2011-03-23 JP JP2013500647A patent/JP2013523629A/ja not_active Ceased
- 2011-03-23 RU RU2012145278/15A patent/RU2012145278A/ru not_active Application Discontinuation
- 2011-03-23 BR BR112012022377A patent/BR112012022377A2/pt not_active IP Right Cessation
- 2011-03-23 EP EP11712680A patent/EP2550005A1/en not_active Withdrawn
- 2011-03-23 MX MX2012010343A patent/MX2012010343A/es not_active Application Discontinuation
- 2011-03-23 CN CN2011800157799A patent/CN102883735A/zh active Pending
- 2011-03-23 AU AU2011231173A patent/AU2011231173A1/en not_active Abandoned
- 2011-03-23 CA CA2792470A patent/CA2792470A1/en not_active Abandoned
- 2011-03-23 KR KR1020127027694A patent/KR20130062275A/ko not_active Withdrawn
- 2011-03-23 WO PCT/IE2011/000019 patent/WO2011117851A1/en not_active Ceased
- 2011-03-23 US US13/637,244 patent/US20130085105A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013523629A5 (OSRAM) | ||
| RU2012145278A (ru) | Трансдермальное введение пептидов | |
| JP2010526190A5 (OSRAM) | ||
| AR067701A1 (es) | Metodos y composiciones utiles para la preparacion de inhibidores del contransportador de sodio y glucosa 2 | |
| JP2012211164A5 (OSRAM) | ||
| TW200800143A (en) | Phenylephrine liquid formulations | |
| JP2012502037A5 (OSRAM) | ||
| MX385798B (es) | Composiciones orales que contienen un ester de 17-hidroxiprogesterona y metodos relacionados. | |
| WO2010051541A3 (en) | Compositions containing delta-9-thc-amino acid esters and process of preparation | |
| JP2009502025A5 (OSRAM) | ||
| JP2009545527A5 (OSRAM) | ||
| JP2010090168A5 (OSRAM) | ||
| UY39192A (es) | Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende | |
| WO2016210003A3 (en) | 17-hydroxyprogesterone ester-containing oral compositions and related methods | |
| JPWO2000038731A1 (ja) | 外用剤 | |
| JP2011510048A (ja) | 低減したアルコール相互作用を有する乱用抵抗性溶融押出製剤 | |
| UA105057C2 (uk) | Композиція 1-[2-(2,4-диметилфенілсульфаніл)феніл]-піперазину | |
| CN103384518A (zh) | 新的抗真菌组合物 | |
| JP2009532434A5 (OSRAM) | ||
| JP2015535274A5 (OSRAM) | ||
| JP2013530208A5 (OSRAM) | ||
| JPWO2008081829A1 (ja) | 難水溶性薬物の溶解性維持用アミノアルキルメタアクリレートコポリマーe | |
| CN1681534A (zh) | 药物吸收性改善剂 | |
| JP2009527467A5 (OSRAM) | ||
| CN110139641A (zh) | 外用组合物 |